The Binding Site Group Limited

For over a quarter of a century, we have been supplying the world's laboratories with the clinical diagnostic tools to effectively diagnose and monitor disease.

Binding Site was founded by a group of researchers from the Medical School at Birmingham University, UK. In the early 1970s, this group were researching innovative ways of producing antibodies. Today, we continue to build upon our specialist protein heritage offering an expanding menu of over 200 protein assays across a range of clinical diagnostic systems.

As demand grew for our expanding range of specialist protein assays, we introduced clinical diagnostic systems into our product offering in late 2007. Together, our specialist protein systems and assays provide laboratories with a complete specialist protein solution.

Our flagship assay, Freelite®, is the only serum free light chain assay recommended by national and international guidelines for the diagnosis, prognosis and monitoring of Multiple Myeloma and other B cell dyscrasias (cancers of the plasma cells). Our specialist protein systems are optimised for running Freelite® and other high sensitivity assays.

Understanding the impact of laboratory diagnostics on clinical patient management, we have never lost sight of the ultimate beneficiary of our products – the patient.

Binding Site – Committed to improving patient lives worldwide through education, collaboration and innovation.